Rushang Patel, MD

Overview

Rushang Patel, MD completed fellowships in bone marrow transplant at Temple University and in hematology/oncology at Fox Chase Cancer Center, one of only 21 prestigious National Comprehensive Cancer Networks (NCCN) in the country. Board-certified in internal medicine and board eligible in medical oncology and hematology, Dr. Patel brings a wealth of clinical knowledge and in-depth research experience to both patient and practice, having worked on projects for United Nations International Children's Emergency Fund (UNICEF), Alembic Pharmaceuticals and Sanofi-Aventis, as well as having conducted studies focused on the mechanisms of cancer formation due to toxic chemicals and identifying new targets for designing cancer drugs

Articles

Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes

LEUKEMIA RESEARCH

2021

Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective

TRANSPLANTATION AND CELLULAR THERAPY

2021

Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on Antimicrobial Management in Adults with Hematological Malignancies and Transplant Recipients with Suspected Infections

TRANSPLANTATION AND CELLULAR THERAPY

2021

Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation

DIAGNOSTICS

2021

Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia

LEUKEMIA & LYMPHOMA

2020

Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

2019

Increased bone marrow CD56(bright) natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome

BONE MARROW TRANSPLANTATION

2019

Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

2019

Addition of Cladribine: Improving Standard of Care in Newly Diagnosed Acute Myeloid Leukemia

BLOOD

2018

Clinical Utility of Multiple-Gene Mutation Testing By Next-Generation Sequencing in Acute Myeloid Leukemia in Community Hospital Setting

BLOOD

2018

Associated Clinical Trials

NCT03147742

An Open-label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

The purpose of the Program is to give access to the investigational drug, ruxolitinib, to GVHD patients in the United States who are not eligible or able to participate in clinical trials conducted by the Sponsor. A second obje ...

NCT04266795

A Randomized, Open-Label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

The purpose of the study is to determine whether treatment with investigational drug pevonedistat in combination with venetoclax and azacitidine improves the time you live as well as the time you live without worsening of your ...

NCT03926624

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine Decitabine, Venetoclax combination regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage.

This study is currently enrolling.

This study will investigate whether a new experimental treatment, DFP-10917, will be an effective and safe treatment option for patients with relapsed/refractory acute myelogenous leukemia (AML). The purpose of this study is to ...

Rushang Patel, MD

Overview

Articles

Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes

Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective

Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on Antimicrobial Management in Adults with Hematological Malignancies and Transplant Recipients with Suspected Infections

Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation

Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation

Increased bone marrow CD56(bright) natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome

Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy

Addition of Cladribine: Improving Standard of Care in Newly Diagnosed Acute Myeloid Leukemia

Clinical Utility of Multiple-Gene Mutation Testing By Next-Generation Sequencing in Acute Myeloid Leukemia in Community Hospital Setting

Education & Training

Education

Residency

Fellowship

Specialty

Board Certifications

Associated Clinical Trials

An Open-label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

A Randomized, Open-Label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine Decitabine, Venetoclax combination regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage.

Explore

Institutes